SCEMBLIX Drug Patent Profile

Which patents cover Scemblix, and when can generic versions of Scemblix launch?

Scemblix is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug.

This drug has eighty-nine patent family members in fifty countries.

The generic ingredient in SCEMBLIX is asciminib hydrochloride. One supplier is listed for this compound. Additional details are available on the asciminib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Scemblix

Scemblix was eligible for patent challenges on October 29, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 14, 2040. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SCEMBLIX

International Patents:	89
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Drug Prices:	Drug price information for SCEMBLIX
What excipients (inactive ingredients) are in SCEMBLIX?	SCEMBLIX excipients list
DailyMed Link:	SCEMBLIX at DailyMed

See drug prices for SCEMBLIX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SCEMBLIX

NDA:

215358

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SCEMBLIX

SCEMBLIX is protected by four US patents and eight FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	No
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-002	Oct 29, 2021		RX	Yes	Yes
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	No				Y
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No				Y
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-002	Oct 29, 2021		RX	Yes	Yes

International Patents for SCEMBLIX

When does loss-of-exclusivity occur for SCEMBLIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

European Patent Office

Israel

Japan

Mexico

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SCEMBLIX around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	C00287
South Africa	201407065
Peru	20161416
Montenegro	03095
Slovenia	2861579
Uruguay	34811
World Intellectual Property Organization (WIPO)	2013171642

Supplementary Protection Certificates for SCEMBLIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2861579	301201	Netherlands		PRODUCT NAME: ASCIMINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS ASCIMINIBHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1670 20220826
2861579	C202230056	Spain		PRODUCT NAME: ASCIMINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, TAL COMO HIDROCLORURO DE ASCIMINIB; NATIONAL AUTHORISATION NUMBER: EU/1/22/1670; DATE OF AUTHORISATION: 20220825; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1670; DATE OF FIRST AUTHORISATION IN EEA: 20220825
2861579	SPC/GB22/044	United Kingdom		PRODUCT NAME: ASCIMINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS ASCIMINIB HYDROCHLORIDE; REGISTERED: UK PLGB00101/1207-0001 20220615; UK PLGB00101/1208-0001 20220615; UK SEE ALSO MA ON IPSUM 20220615
2861579	C20220039 00385	Estonia		PRODUCT NAME: ASTSIMINIIB;REG NO/DATE: EU/1/22/1670 26.08.2022
2861579	PA2022523,C2861579	Lithuania		PRODUCT NAME: ASCIMINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TOKIA KAIP ASCIMINIBO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/22/1670 20220825
2861579	122022000072	Germany		PRODUCT NAME: ASCIMINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON, WIE ZUM BEISPIEL ASCIMINIBHYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1670 20220825
2861579	LUC00287	Luxembourg		PRODUCT NAME: ASCIMINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS ASCIMINIB HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1670 20220826

Market Dynamics and Financial Trajectory for SCEMBLIX (Avapritinib)

Last updated: July 27, 2025

---

Introduction

SCEMBLIX (avapritinib) has emerged as a significant player within the targeted oncology therapeutic landscape. As a potent, selective inhibitor of KIT and PDGFRA mutant kinases, SCEMBLIX addresses unmet needs in treating gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM). Its market trajectory hinges upon evolving clinical data, regulatory pathways, competitive positioning, and broader industry trends. This analysis examines the key market dynamics shaping SCEMBLIX's commercial potential and forecasts its financial trajectory within this high-stakes domain.

---

Market Overview

Oncology Therapeutic Market Context

The global oncology market, valued at approximately USD 200 billion in 2022, continues to expand at a compound annual growth rate (CAGR) of over 6% (source: IQVIA). Targeted therapies and precision medicine constitute a central growth pillar, driven by advances in molecular diagnostics, biomarker identification, and personalized treatment approaches. SCEMBLIX, as a targeted kinase inhibitor, fits into this rapidly evolving segment, with its indications spanning GIST, systemic mastocytosis, and potential off-label applications.

Indication-Specific Market Sizes

• Gastrointestinal Stromal Tumors (GIST): Estimated global market size exceeds USD 1 billion, with primary competition from tyrosine kinase inhibitors like imatinib, sunitinib, regorafenib, and ripretinib. The niche for subsequent-line therapies remains appraised at roughly USD 300–500 million annually, reflective of late-stage resistant or intolerant GIST patient segments (source: Global Data).

• Systemic Mastocytosis (SM): A rare disorder with an estimated prevalence of 1 in 10,000 to 20,000, leading to a lower but clinically significant market segment. The U.S. SM market is approximated at USD 50 million, with potential for growth as SCEMBLIX gains regulatory approval and indications expand.

Key Market Drivers

1. Unmet Medical Needs and Orphan Disease Status

SCEMBLIX addresses critical gaps in resistant GIST and systemic mastocytosis management. Its high specificity and potency enable it to overcome resistance mechanisms associated with earlier-generation TKIs, such as imatinib or sunitinib. Orphan drug designation accelerates its pathway to market and provides commercialization incentives.

2. Regulatory Approvals and Milestones

As of early 2023, SCEMBLIX has secured FDA approval for GIST patients with PDGFRA exon 18 mutations, including the D842V subtype—traditionally resistant to other TKIs. European Medicines Agency (EMA) approvals are anticipated, extending its commercial reach. Further, pivotal trials for SM indications are underway, promising expanded indications.

3. Competitive Landscape

While imatinib remains the first-line standard of care in GIST, resistance development prompts physicians to seek second- and third-line options like avapritinib. Ripretinib, approved for advanced GIST, and other emerging agents create a competitive backdrop. For systemic mastocytosis, drugs like midostaurin and newer agents vie for market share, but SCEMBLIX's selectivity offers differentiation.

4. Clinical Data and Real-World Evidence (RWE)

Initial trial results demonstrate durable response rates and manageable safety profiles. Continued accumulation of RWE will influence physician adoption, reimbursement negotiations, and formulary placements, all critical for revenue growth.

---

Market Challenges and Risks

1. Pricing and Reimbursement Dynamics

Pricing strategies for innovative TKIs are pivotal. Given the high cost associated with precision therapies, payers may impose strict reimbursement criteria, especially in mature markets. Demonstrating clear cost-effectiveness and survival benefits remains essential for favorable formulary access.

2. Patent Protection and Pipeline Development

Patents typically provide exclusivity for approximately 20 years from filing. Any patent challenges or potential generics could erode the financial horizon. An active development pipeline aimed at broader indications or combination regimens could prolong revenue streams.

3. Competitive Advancements and Biosimilars

Emerging agents leveraging novel mechanisms (e.g., allosteric inhibitors, immunotherapies) threaten SCEMBLIX's market share in GIST and SM. Additionally, biosimilar competition for other TKIs may influence overall market dynamics.

---

Financial Trajectory and Revenue Forecasts

1. Revenue Generation Timeline

• 2023-2024: Initial commercial sales of SCEMBLIX begin in approved indications. Early revenues likely modest, contingent upon market penetration and prescriber awareness campaigns.
• 2025-2027: As global approvals expand and dosing familiarity increases, revenues are projected to grow at a CAGR of 20–30%, reaching USD 500–700 million in mid-term estimates.
• Post-2027: Expansion into additional indications, such as other mutant-driven tumors or combinatorial regimens, could further augment revenues, especially if new approvals are achieved.

2. Key Revenue Drivers

• Market Penetration: Adoption by major healthcare providers and adoption into treatment guidelines influence sales volume.
• Pricing Strategy: Premium pricing justified by clinical benefits sustainsMargins, but reimbursement landscapes may adjust this trajectory.
• Market Expansion: Geographic expansion into emerging markets can contribute incremental revenues, though at lower price points.

3. Investment and Cost Implications

Significant R&D investments fortify pipeline growth, while manufacturing scaling affects margins. Costs related to clinical trials, regulatory filings, and commercialization efforts are front-loaded but diminish over time as revenues grow.

---

Strategic Outlook

The financial outlook for SCEMBLIX remains optimistic, bolstered by its targeted, mechanism-specific benefits, regulatory support, and unmet medical needs. Companies investing in strategic partnerships, differentiated marketing approaches, and pipeline diversification position themselves for sustained growth.

To maximize financial trajectories, sustained focus on clinical data maturation, payer engagement, global regulatory submissions, and competitive intelligence will be essential. As the landscape evolves, agility in strategy and patient-centric approaches will determine long-term success.

---

Key Takeaways

• High Growth Potential: SCEMBLIX’s targeted approach facilitates rapid penetration into niche markets like resistant GIST and systemic mastocytosis, with projected revenues reaching USD 500–700 million within five years.
• Pipeline and Indication Expansion: Broader use cases and additional indications promise substantial revenue diversification and growth.
• Market Challenges: Pricing and reimbursement hurdles, competitive advances, and patent protections require vigilant strategic planning.
• Strategic Positioning: Continued clinical validation and geographic expansion will be instrumental in solidifying market share.
• Investment Imperative: Balancing R&D investments with commercialization efforts will determine financial sustainability and long-term profitability.

---

FAQs

1. What are the primary indications for SCEMBLIX?
SCEMBLIX is approved primarily for gastrointestinal stromal tumors harboring PDGFRA exon 18 mutations, including the D842V mutation, and is under clinical development for systemic mastocytosis.

2. How does SCEMBLIX compare to existing therapies?
SCEMBLIX exhibits higher selectivity and potency against resistant KIT and PDGFRA mutants, offering improved efficacy in cases resistant to first-line TKIs like imatinib, with a manageable safety profile.

3. What is the current regulatory status of SCEMBLIX?
As of 2023, SCEMBLIX has received FDA approval for specific GIST mutations, with European approval anticipated and ongoing clinical trials supporting broader indications.

4. What are the main hurdles affecting its commercial success?
Key challenges include navigating reimbursement landscapes, establishing physician awareness, competing therapies, and potential patent expirations.

5. What is the revenue forecast for SCEMBLIX over the next five years?
Assuming strategic execution, revenues could reach USD 500–700 million by 2028, driven by increased market penetration, extended indications, and geographic expansion.

---

References

[1] IQVIA Institute for Human Data Science. The Global Oncology Market Report, 2022.
[2] Global Data. Oncology Therapeutics Market Analysis, 2022.
[3] U.S. Food and Drug Administration. SCEMBLIX (avapritinib) approval documentation, 2023.
[4] European Medicines Agency. Pending approval updates, 2023.